Arcturus Therapeutics Holdings Inc. (ARCT) stock rallied over 16.96% intraday to trade at $18.90 a share on NASDAQ. The stock opened with a gain of 20.38% at $15.64 and touched an intraday high of $18.9, rising 16.96% against the last close of $16.16. The stock went to a low of $15.5 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue12.36 Million
5Y Sales Change-9.50%
Fiscal Year Ends2021-12-30
Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) stock price is $18.9 as of the last check on Tuesday, July 5. During the trading session, ARCT stock reached the peak price of $18.9 while $15.5 was the lowest point it dropped to.
The NASDAQ listed ARCT is part of Biotechnology industry that operates in the broader Health Care sector. Arcturus Therapeutics Holdings Inc. , an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States.
Dr. Steven George Hughes M.B.A., M.D.
Chief Medical Officer
Ms. Neda Safarzadeh
Sr. Director and Head of Investor Relations/PR & Marketing
Dr. Nirdosh Jagota Ph.D.
Exec. VP & Chief Regulatory Officer
Mr. Joseph E. Payne M.Sc.
Founder, Pres, CEO & Director
ARCT stock traded closed the last session at $18.9, which is $2.74 or 16.96% lower than its previous close of $16.16. ARCT's current trading price is 61.54% lower than its 52-week high of $65.00 where as its distance from 52-week low of 11.70% is -70.92%.
Number of ARCT employees currently stands at -. ARCT operates from 10628 Science Center Drive, Suite 250, San Diego, CA 92121, United States.
Official Webiste of $ARCT is: https://arcturusrx.com
ARCT stock volume for the day was 714,802 shares while in the previous session number of ARCT shares traded was 662,980 . The average number of ARCT shares traded daily for last 3 months was 759.16 Thousands.
The percentage change in ARCT stock occurred in the recent session was 16.96% while the dollar amount for the price change in ARCT stock was $2.74.
In the recent session, the day high for ARCT stock was $18.9 while the low for ARCT stock touched on the day was $15.5.
The market value of ARCT currently stands at 486.3 Million with its latest stock price at $18.9 and 26.38 Million of its shares outstanding.